Invivyd Announces Executive Leadership Shakeup and Strategic FDA Alignment
Company Announcements

Invivyd Announces Executive Leadership Shakeup and Strategic FDA Alignment

Invivyd (IVVD) just unveiled an update.

Invivyd, Inc. recently underwent significant leadership changes, with the departure of Jeremy Gowler as its interim CEO, COO, and CCO, and the appointment of William Duke, Jr. as the new principal executive officer from May 30, 2024. Duke, a seasoned professional with over 25 years in finance and senior leadership roles in biotech, continues to serve as CFO and will lead the company following Gowler’s exit on June 29, 2024. Additionally, Timothy Lee has been named Chief Commercial Officer, reinforcing the company’s executive team. These changes come amid Invivyd’s strategic alignment with the FDA on an innovative approach for potential emergency use authorizations of COVID-19 monoclonal antibodies.

Learn more about IVVD stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyInvivyd announces manuscript preprint conveying data from CANOPY Phase 3 trial
Jason CarrIVVD Upcoming Earnings Report: What to Expect?
TheFlyU.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App